rhigm22
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01803867)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- MERS-CoVImmunity, passive
MERS-CoV immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- m22
- rhigm22
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02398461 | Phase 1 | Apr 1, 2015 | Acorda Therapeutics, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT01803867 | Phase 1 | Mar 1, 2013 | Acorda Therapeutics, Pharmaceutical Research Associates, Inc. (PRA) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acorda Therapeutics | For profit | 2 | 2 | 1 | 2013 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 2 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1